Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer

INTRODUCTION: PD-L1 expression in non-small cell lung cancer (NSCLC) predicts response to immune checkpoint blockade, however is an imperfect biomarker given tumor heterogeneity, and the antigen presentation pathway requiring other components including HLA I expression. HLA I downregulation may cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Schehr, Jennifer L., Sethakorn, Nan, Schultz, Zachery D., Hernandez, Camila I., Bade, Rory M., Eyzaguirre, Diego, Singh, Anupama, Niles, David J., Henderson, Leslie, Warrick, Jay W., Berry, Scott M., Sundling, Kaitlin E., Beebe, David J., Leal, Ticiana A., Lang, Joshua M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040226/
https://www.ncbi.nlm.nih.gov/pubmed/35468853
http://dx.doi.org/10.1186/s40364-022-00370-8

Ejemplares similares

Ejemplares similares